US 9,534,234 C1 (12,518th)
Enhanced nucleic acid constructs for eukaryotic gene expression
Jeremy Minshull, Los Alston, CA (US); Mark Welch, Fremont, CA (US); Sridhar Govindrajan, Los Altos, CA (US); and Kate Caves, San Jose, CA (US)
Filed by DNA2.0, INC., Menlo Park, CA (US)
Assigned to DNA2.0, INC., Menlo Park, CA (US)
Reexamination Request No. 90/014,365, Aug. 12, 2019.
Reexamination Certificate for Patent 9,534,234, issued Jan. 3, 2017, Appl. No. 14/683,126, Apr. 9, 2015.
Claims priority of provisional application 62/120,522, filed on Feb. 25, 2015.
Claims priority of provisional application 62/069,656, filed on Oct. 28, 2014.
Claims priority of provisional application 62/046,705, filed on Sep. 5, 2014.
Claims priority of provisional application 62/046,875, filed on Sep. 5, 2014.
Claims priority of provisional application 62/003,397, filed on May 27, 2014.
Claims priority of provisional application 61/977,474, filed on Apr. 9, 2014.
Ex Parte Reexamination Certificate issued on Feb. 16, 2024.
Int. Cl. C12N 15/63 (2006.01); A61K 31/00 (2006.01); A61K 31/7105 (2006.01); C07K 2/00 (2006.01); C07K 14/435 (2006.01); C07K 14/46 (2006.01); C07K 16/00 (2006.01); C07K 16/32 (2006.01); C12N 9/12 (2006.01); C12N 15/85 (2006.01); C12N 15/90 (2006.01); A61K 38/00 (2006.01)
CPC C12N 9/1241 (2013.01) [A61K 31/00 (2013.01); A61K 31/7105 (2013.01); C07K 2/00 (2013.01); C07K 14/43586 (2013.01); C07K 14/463 (2013.01); C07K 16/00 (2013.01); C07K 16/32 (2013.01); C12N 15/85 (2013.01); C12N 15/907 (2013.01); C12Y 207/07 (2013.01); A61K 38/00 (2013.01); C07K 2317/10 (2013.01); C07K 2317/24 (2013.01); C07K 2317/56 (2013.01); C07K 2319/09 (2013.01); C07K 2319/80 (2013.01); C12N 2800/90 (2013.01); C12N 2830/40 (2013.01); C12N 2830/60 (2013.01)]
AS A RESULT OF REEXAMINATION, IT HAS BEEN DETERMINED THAT:
The patentability of claims 1-2 and 5-6 is confirmed.
Claim 3 is determined to be patentable as amended.
New claims 7-8 are added and determined to be patentable.
Claim 4 was not reexamined.
3. The polynucleotide of claim 2, wherein the heterologous [ DNA sequence of the transposon comprises a ] promoter is operably linked to at least one or more of: i) an open reading frame; ii) a nucleic acid encoding a selectable marker; iii) a nucleic acid encoding a counter-selectable marker; iii) a nucleic acid encoding a regulatory protein; iv) a nucleic acid encoding an inhibitory RNA.
[ 7. The polynucleotide of claim 3, wherein the selectable marker is glutamine synthetase.]
[ 8. The polynucleotide of claim 3, wherein the selectable marker is dihydrofolate reductase.]